LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 110 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is 0.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $64 | -12.3% | 54,482 | +5.8% | 0.00% | – |
| Q2 2023 | $73 | +1.4% | 51,482 | +6.2% | 0.00% | – |
| Q1 2023 | $72 | +26.3% | 48,489 | -1.0% | 0.00% | – |
| Q4 2022 | $57 | -99.9% | 48,989 | +14.0% | 0.00% | – |
| Q3 2022 | $48,000 | -32.4% | 42,990 | -5.5% | 0.00% | – |
| Q2 2022 | $71,000 | +1.4% | 45,490 | +0.0% | 0.00% | – |
| Q1 2022 | $70,000 | -25.5% | 45,489 | +17.8% | 0.00% | – |
| Q4 2021 | $94,000 | -14.5% | 38,629 | -12.1% | 0.00% | – |
| Q3 2021 | $110,000 | -28.6% | 43,939 | -19.1% | 0.00% | – |
| Q2 2021 | $154,000 | +36.3% | 54,339 | +12.4% | 0.00% | – |
| Q1 2021 | $113,000 | -28.5% | 48,325 | -46.2% | 0.00% | – |
| Q4 2020 | $158,000 | +85.9% | 89,829 | -1.7% | 0.00% | – |
| Q3 2020 | $85,000 | +14.9% | 91,419 | +7.0% | 0.00% | – |
| Q2 2020 | $74,000 | +21.3% | 85,419 | +14.2% | 0.00% | – |
| Q1 2020 | $61,000 | +3.4% | 74,828 | +11.7% | 0.00% | – |
| Q4 2019 | $59,000 | -47.3% | 67,010 | -41.4% | 0.00% | – |
| Q3 2019 | $112,000 | – | 114,358 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $41,223,872 | 3.66% |
| Raffles Associates | 1,587,739 | $1,873,532 | 2.48% |
| Defender Capital, LLC. | 5,184,510 | $6,117,722 | 2.22% |
| Prescott General Partners LLC | 1,851,851 | $2,185,184 | 0.14% |
| DCF Advisers, LLC | 82,751 | $97,646 | 0.05% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $63,450 | 0.05% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 781,766 | $922,484 | 0.02% |
| Fort Sheridan Advisors LLC | 83,931 | $99,039 | 0.02% |
| MAI Capital Management | 954,688 | $1,126,532 | 0.02% |
| Piscataqua Savings Bank | 12,499 | $14,623 | 0.01% |